Advertisement

Author: Rylee Wilson

Leqembi, the newly-approved drug that can slow the progression of Alzhemier's disease, will cost Medicare billions each year, according to an analysis from KFF. 

Advertisement

As more employees work in remote or hybrid formats, payers are cutting back on office space nationwide. 

Advertisement